Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Phase 1 Recruiting
300 enrolled
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Recruiting
38 enrolled
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Phase 1/2 Recruiting
260 enrolled
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1 Recruiting
86 enrolled
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Phase 1/2 Recruiting
420 enrolled
MonumenTAL-1
Phase 2 Recruiting
510 enrolled 1 FDA
MK-3475-587
Phase 3 Recruiting
3,500 enrolled
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Phase 1/2 Recruiting
160 enrolled
MK-1026-003
Phase 2 Recruiting
490 enrolled
Role of Gut Microbiome in Cancer Therapy
Recruiting
3,000 enrolled
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Phase 1 Recruiting
420 enrolled
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Phase NA Recruiting
100 enrolled
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Phase 1/2 Recruiting
70 enrolled
CARE-T
Phase NA Recruiting
100 enrolled
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Phase 1 Recruiting
60 enrolled
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Recruiting
135 enrolled
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Recruiting
88 enrolled
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
Phase NA Recruiting
256 enrolled
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
Phase 2 Recruiting
312 enrolled
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Phase 2 Recruiting
46 enrolled
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Phase 1 Recruiting
30 enrolled
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Phase 3 Recruiting
360 enrolled
Discontinuation Study
Phase NA Recruiting
70 enrolled
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Phase 1 Recruiting
20 enrolled
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Phase 1 Recruiting
20 enrolled
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Recruiting
12,000 enrolled
HORIZONS
Phase NA Recruiting
350 enrolled
Aquarius
Recruiting
550 enrolled
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
Phase NA Recruiting
38 enrolled
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Phase 2 Recruiting
12 enrolled
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Phase 1/2 Recruiting
265 enrolled
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Phase 2 Recruiting
15 enrolled
Organoid
Recruiting
70 enrolled
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Phase 3 Recruiting
105 enrolled
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Phase NA Recruiting
2,000 enrolled
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Phase NA Recruiting
400 enrolled
The Florida ASCENT Study
Phase NA Recruiting
100 enrolled
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
Recruiting
170 enrolled
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting
30 enrolled
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Phase 2 Recruiting
40 enrolled
The Impact of COVID-19 on Pulmonary Procedures
Recruiting
250 enrolled
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting
99,999 enrolled
SPI-FOL-102
Phase 1 Recruiting
24 enrolled
Genomic Profiling in Cancer Patients
Recruiting
200 enrolled
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
280 enrolled
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Recruiting
6,000 enrolled
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Phase 1/2 Recruiting
31 enrolled
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recruiting
2,000 enrolled
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Phase 1/2 Recruiting
64 enrolled
IVIG for Infection Prevention After CAR-T-Cell Therapy
Phase 2 Recruiting
150 enrolled